Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer
Frontiers in Oncology · 19.08.2026 · 16
DOI: 10.3389/fonc.2026.1867321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.08.2026. Verfasst von Hongbing Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospit…. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin Municipality, Tianjin Municipal Health Commission.
Abstract (Originalsprache)
Background
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major challenge in non-small cell lung cancer (NSCLC) treatment. Although ascomycin (FK520) has demonstrated some antitumor activity, its potential in overcoming osimertinib resistance has not been fully characterized.
Methods
Cell viability and proliferation were assessed using the Cell Counting Kit 8 (CCK8) and colony formation assays, respectively, following treatment with ascomycin, osimertinib, or interleukin (IL)-6 for 48 h. Flow cytometry was employed to characterize cell cycle distribution and apoptotic rates. To identify key regulatory pathways, transcriptomic profiling was performed via RNA sequencing. The expression of relevant molecular targets was quantified using western blotting, and quantitative PCR (qPCR). Finally, the chemosensitizing effect of ascomycin was validated in vivousing established animal models.
Results
Ascomycin were observed to significantly enhanced the antiproliferative effects of osimertinib in EGFR-TKI-resistant lung cancer cells. Further analysis indicated that such effects may be mediated, at least in part, by modulating the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling pathway and promoting tumor cell apoptosis. Consistent with in vitro results, combined ascomycin and osimertinib treatment generated greater antitumor efficacy than either agent alone in osimertinib-resistant NSCLC xenograft models.
Conclusions
Ascomycin may be an effective adjuvant in enhancing osimertinib therapeutic activity and overcoming acquired EGFR-TKI resistance, thereby providing a promising combination strategy for treating resistant NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin Municipality
- Tianjin Municipal Health Commission
Zitieren
APA
Zhang, H., Chen, C., Wu, D., Li, W., Gong, H., Liu, C., Wu, H., Zhang, Q., Liu, H., Chen, J., & Li, Y. (2026). Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1867321
Vancouver
Zhang H, Chen C, Wu D, Li W, Gong H, Liu C, et al. Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1867321
BibTeX
@article{Zhang2026,
author = {Zhang, Hongbing and Chen, Chen and Wu, Di and Li, Weiting and Gong, Hao and Liu, Chao and Wu, Hongfeng and Zhang, Quan and Liu, Hongyu and Chen, Jun and Li, Yongwen},
title = {Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1867321}
}
EUVIMED